-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the aging of the population, changes in life>
.
It is worth noting that with the continuous expansion of the ophthalmic treatment market, the development of this market is increasingly favored by the industry, and domestic and foreign pharmaceutical companies are also accelerating their deployment in this field
.
Recently, Novartis announced an agreement to acquire all the remaining shares of Gyroscope Therapeutics, a British-based eye gene therapy company
.
According to the agreement, Novartis will pay an advance payment of US$800 million and potential additional milestone payments of up to US$700 million
.
It is understood that Novartis will obtain the one-time gene therapy GT005 under research through this acquisition, which is undergoing phase 2 clinical trials for the treatment of geographic atrophy (GA)
.
On December 20, Lineage Cell Therapeutics announced that it has signed a global exclusive cooperation and licensing agreement with its subsidiary Cell Cure Neurosciences and Roche subsidiary Genentech to jointly develop and commercialize retinal pigment epithelial (RPE) cell therapy to treat eye diseases.
Including advanced dry age-related macular degeneration (AMD) with geographic atrophy (GA)
.
According to the terms of the cooperation agreement, Genentech will be responsible for the further clinical development and commercialization of Lineage's OpRegen® project, and Lineage will complete the work related to the ongoing clinical research (registration has been completed) and perform certain manufacturing tasks
.
At that time, Genentech will also pay $50 million in advance to Lineage, and Lineage will be eligible for up to $620 million in additional development, approval and sales milestone payments, as well as double-digit tiered royalties
.
The above companies are just the epitome of multinational pharmaceutical companies entering the field of ophthalmology treatment.
With large investment and innovation, the ophthalmology medical market has long been dominated by foreign giants
.
However, in recent years, with the continuous increase of domestic developers' investment in ophthalmic drug R&D and the continuous improvement of innovation capabilities, local pharmaceutical companies have begun to make breakthroughs in the field of ophthalmic treatment, and more domestic drugs with innovative points and combination therapies are gradually emerging
.
For example, on November 30, Hengrui Medicine announced the primary study endpoint of a multi-center, randomized, double-blind, salt solution parallel controlled phase III clinical trial (SHR8058-301) of SHR8058 eye drops for the treatment of dry eye related to meibomian gland dysfunction.
As a result, it reaches the pre-established superiority standard of the plan, and will submit a pre-market communication application to CDE in the near future
.
According to data, SHR8058 eye drops are NOV03 (perfluorohexyl octane) introduced by Hengrui Medicine from Novaliq GmbH.
It can treat meibomian gland dysfunction by forming a stable envelope on the eye surface and preventing excessive tears from evaporating.
Related evaporative dry eye syndrome
.
It is worth mentioning that, in addition to SHR8058 eye drops, the tafluprost eye drops declared by Chengdu Shengdi Pharmaceutical Co.
, Ltd.
, a subsidiary of Hengrui Pharmaceuticals, has been approved for marketing, becoming the first imitation of the product
.
In addition, prior to this, Osaikang also issued an announcement stating that the company’s application for clinical trials of the new drug ASKG712 for injection has been accepted.
Edema) and RVO-ME (macular edema secondary to branch retinal vein occlusion) and so on
.
Data show that ASKG712 for injection is a dual-targeting anti-VEGF-A humanized monoclonal antibody-Ang-2 inhibitory peptide fusion protein with independent intellectual property rights developed by the company
.
In addition to the above companies, since this year, a large number of domestic pharmaceutical companies have also entered the ophthalmic treatment track through self-research, introduction, and cooperation
.
In addition, many companies have chosen to cooperate with schools and are beginning to vigorously cultivate professional talents in ophthalmology
.
In this context, the industry believes that from the current ophthalmology market there are still far from being satisfied clinical needs, and the urgent need for innovative therapeutic drugs and methods, related companies will usher in huge development opportunities and increasingly fierce competition
.
But at the same time, domestic pharmaceutical companies also need to further strengthen technological innovation, increase market development, and enhance the company's sales coverage capabilities in order to better compete with foreign companies in a larger market
.
.
It is worth noting that with the continuous expansion of the ophthalmic treatment market, the development of this market is increasingly favored by the industry, and domestic and foreign pharmaceutical companies are also accelerating their deployment in this field
.
Recently, Novartis announced an agreement to acquire all the remaining shares of Gyroscope Therapeutics, a British-based eye gene therapy company
.
According to the agreement, Novartis will pay an advance payment of US$800 million and potential additional milestone payments of up to US$700 million
.
It is understood that Novartis will obtain the one-time gene therapy GT005 under research through this acquisition, which is undergoing phase 2 clinical trials for the treatment of geographic atrophy (GA)
.
On December 20, Lineage Cell Therapeutics announced that it has signed a global exclusive cooperation and licensing agreement with its subsidiary Cell Cure Neurosciences and Roche subsidiary Genentech to jointly develop and commercialize retinal pigment epithelial (RPE) cell therapy to treat eye diseases.
Including advanced dry age-related macular degeneration (AMD) with geographic atrophy (GA)
.
According to the terms of the cooperation agreement, Genentech will be responsible for the further clinical development and commercialization of Lineage's OpRegen® project, and Lineage will complete the work related to the ongoing clinical research (registration has been completed) and perform certain manufacturing tasks
.
At that time, Genentech will also pay $50 million in advance to Lineage, and Lineage will be eligible for up to $620 million in additional development, approval and sales milestone payments, as well as double-digit tiered royalties
.
The above companies are just the epitome of multinational pharmaceutical companies entering the field of ophthalmology treatment.
With large investment and innovation, the ophthalmology medical market has long been dominated by foreign giants
.
However, in recent years, with the continuous increase of domestic developers' investment in ophthalmic drug R&D and the continuous improvement of innovation capabilities, local pharmaceutical companies have begun to make breakthroughs in the field of ophthalmic treatment, and more domestic drugs with innovative points and combination therapies are gradually emerging
.
For example, on November 30, Hengrui Medicine announced the primary study endpoint of a multi-center, randomized, double-blind, salt solution parallel controlled phase III clinical trial (SHR8058-301) of SHR8058 eye drops for the treatment of dry eye related to meibomian gland dysfunction.
As a result, it reaches the pre-established superiority standard of the plan, and will submit a pre-market communication application to CDE in the near future
.
According to data, SHR8058 eye drops are NOV03 (perfluorohexyl octane) introduced by Hengrui Medicine from Novaliq GmbH.
It can treat meibomian gland dysfunction by forming a stable envelope on the eye surface and preventing excessive tears from evaporating.
Related evaporative dry eye syndrome
.
It is worth mentioning that, in addition to SHR8058 eye drops, the tafluprost eye drops declared by Chengdu Shengdi Pharmaceutical Co.
, Ltd.
, a subsidiary of Hengrui Pharmaceuticals, has been approved for marketing, becoming the first imitation of the product
.
In addition, prior to this, Osaikang also issued an announcement stating that the company’s application for clinical trials of the new drug ASKG712 for injection has been accepted.
Edema) and RVO-ME (macular edema secondary to branch retinal vein occlusion) and so on
.
Data show that ASKG712 for injection is a dual-targeting anti-VEGF-A humanized monoclonal antibody-Ang-2 inhibitory peptide fusion protein with independent intellectual property rights developed by the company
.
In addition to the above companies, since this year, a large number of domestic pharmaceutical companies have also entered the ophthalmic treatment track through self-research, introduction, and cooperation
.
In addition, many companies have chosen to cooperate with schools and are beginning to vigorously cultivate professional talents in ophthalmology
.
In this context, the industry believes that from the current ophthalmology market there are still far from being satisfied clinical needs, and the urgent need for innovative therapeutic drugs and methods, related companies will usher in huge development opportunities and increasingly fierce competition
.
But at the same time, domestic pharmaceutical companies also need to further strengthen technological innovation, increase market development, and enhance the company's sales coverage capabilities in order to better compete with foreign companies in a larger market
.
